Comments
WASHINGTON In “The Disarticulation of Pandemic War Propaganda,” a transparent attempt to frame China as the instigator of worldwide lockdown policies was revealed to be the work of a group of self-styled libertarian-minded individuals. Their links to the UK, the United States, and Canadian governments tie a neat Pentagon-size bow around ongoing efforts to demonize the Chinese Communist Party (CCP).
The ‘specter of communism,’ which worked well during the twentieth century as an intimidation factor to break down protectionist policies and impose oppressive debt regimes, is now being revived to resuscitate an economic paradigm that is long past its sell-date.
Global Nursing Education Market 2020 Analysis By Regional, Outlook, Competitive Landscape Strategies pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
®/Jadenu
®, BGJ398, TKI258 (dovitinib) and PDR001. Most recently, he led the development teams to achieve accelerated approval of Tabrecta
® and Zykadia
® in sickle cell disease, all under the US FDA breakthrough therapy designation. We are honored to have Dr. Shi joining the Transcenta team, said Dr. Xueming Qian, Co-Founder and CEO of Transcenta. As a seasoned biopharmaceutical industrial expert, Dr. Shi worked extensively in the areas of clinical development, translational medicine, biomarker development, and discovery research in several well-known companies. He will lead our global clinical development and registration of all therapeutic area products. The biopharmaceutical industry has made great progress in China in recent years, said Dr. Shi. As an integrated biopharmaceutical company focusing on innovative biological products, Transcenta has great potential. I m very excited to join the company and look forward to accelerating the research and development o
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Research from Analysis Group and IHBDH Furthers Understanding of Hemophilia in China
February 9, 2021 GMT
BOSTON, Feb. 9, 2021 /PRNewswire/ Consultants from Analysis Group, a global leader in health economics and outcomes research (HEOR), and the Institute of Hematology & Blood Diseases Hospital (IHBDH), a clinical and research institute of the Chinese Academy of Medical Sciences and Peking Union Medical College, published a pair of studies in the journal Haemophilia advancing the understanding of hemophilia in China. The study results provide critical information on patient characteristics, treatment strategies, and other clinical information needed to aid regulatory decision making, enhance the quality of care, and improve patient outcomes.